Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
Aged
Aged, 80 and over
Current Procedural Terminology
Databases, Factual
/ statistics & numerical data
Electronic Health Records
/ statistics & numerical data
Female
Follow-Up Studies
Herpes Zoster Ophthalmicus
/ epidemiology
Herpes Zoster Vaccine
/ administration & dosage
Humans
Incidence
Male
Medicare Part D
/ statistics & numerical data
Middle Aged
Retrospective Studies
Treatment Outcome
United States
/ epidemiology
Vaccination
Vaccine Efficacy
/ statistics & numerical data
Vaccines, Synthetic
Shingrix vaccine
administrative claims database
herpes zoster ophthalmicus
herpes zoster vaccine
recombinant zoster vaccine
retrospective cohort study
vaccine effectiveness
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
26
02
2021
revised:
08
04
2021
accepted:
12
04
2021
pubmed:
24
4
2021
medline:
25
12
2021
entrez:
23
4
2021
Statut:
ppublish
Résumé
To examine the effectiveness of the recombinant zoster vaccine (RZV) for preventing herpes zoster ophthalmicus (HZO) in the general United States population. Retrospective, observational cohort study. Individuals enrolled in the OptumLabs Data Warehouse (OLDW; OptumLabs, Cambridge, MA) who were age eligible for herpes zoster (HZ) vaccination (≥50 years of age) from 2018 through 2019. The OLDW is a longitudinal, de-identified administrative claims and electronic health record database of patients in the United States with commercial insurance, Medicare Part D, or Medicare Advantage METHODS: Patients were required to have 365 days or more of continuous enrollment to be eligible. Those with a diagnosis code of HZ or an immunocompromising condition within 1 year before study inclusion were excluded. Vaccination with the RZV was ascertained by Current Procedural Terminology codes, and HZO was ascertained by International Classification of Diseases, Tenth Revision, codes. Cox proportional hazards regression models were used to estimate the hazard ratio of HZO associated with RZV, and inverse-probability weighting was used to control for confounding. Vaccine effectiveness was calculated from hazard ratios. Incidence of HZO in vaccinated versus unvaccinated person-times and vaccine effectiveness were assessed. From January 1, 2018, through December 31, 2019, a total of 4 842 579 individuals were included in this study. One hundred seventy-seven thousand two hundred eighty-nine (3.7%) received 2 valid doses of RZV. The incidence rate of HZO was 25.5 cases (95% confidence interval [CI], 17.4-35.8 cases) per 100 000 person-years in the vaccinated group compared with 76.7 cases (95% CI, 74.7-78.7 cases) in the unvaccinated group. The overall adjusted effectiveness of RZV against HZO was 89.1% (95% CI, 82.9%-93.0%). The effectiveness of RZV against HZO in individuals 50 years of age and older is high in a clinical setting. However, the low vaccination rate in this study highlights the public health need to increase HZV use. Ophthalmologists can play an important role in recommending vaccination to eligible patients.
Identifiants
pubmed: 33892049
pii: S0161-6420(21)00287-6
doi: 10.1016/j.ophtha.2021.04.017
pmc: PMC8585578
mid: NIHMS1753598
pii:
doi:
Substances chimiques
Herpes Zoster Vaccine
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1699-1707Subventions
Organisme : NEI NIH HHS
ID : R01 EY028739
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Références
Vaccine. 2020 Mar 23;38(14):2984-2994
pubmed: 32115298
Clin Infect Dis. 2021 Sep 15;73(6):949-956
pubmed: 33580245
Mayo Clin Proc. 2013 Jun;88(6):562-70
pubmed: 23664666
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Ophthalmology. 2020 Mar;127(3):324-330
pubmed: 31668889
Cornea. 2013 Jul;32(7):976-81
pubmed: 23449488
JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
Ophthalmology. 2013 Mar;120(3):451-456
pubmed: 23207173
N Engl J Med. 2005 Jun 2;352(22):2271-84
pubmed: 15930418
Clin Infect Dis. 2012 Apr;54(7):922-8
pubmed: 22291101
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Am J Epidemiol. 2018 Jan 1;187(1):161-169
pubmed: 29309521
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
N Engl J Med. 2013 Jul 18;369(3):255-63
pubmed: 23863052
Ophthalmology. 2016 Jul;123(7):1469-75
pubmed: 27067924
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108
pubmed: 29370152
MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4
pubmed: 18528318
Cornea. 2012 Jul;31(7):786-90
pubmed: 22269677
Clin Infect Dis. 2012 Nov 15;55(10):1320-8
pubmed: 22828595
BMJ Open. 2014 Jun 10;4(6):e004833
pubmed: 24916088
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Vaccine. 2018 Mar 14;36(12):1537-1541
pubmed: 29463421
Expert Rev Vaccines. 2010 Mar;9(3 Suppl):21-6
pubmed: 20192714
JAMA. 2011 Jan 12;305(2):160-6
pubmed: 21224457
Clin Infect Dis. 2015 Mar 15;60(6):900-9
pubmed: 25416754
Ophthalmology. 2008 Feb;115(2 Suppl):S3-12
pubmed: 18243930
Am J Ophthalmol. 2013 May;155(5):787-95
pubmed: 23394910
PLoS Med. 2013;10(4):e1001420
pubmed: 23585738
Open Forum Infect Dis. 2014 Aug 02;1(2):ofu049
pubmed: 25734121
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Eye Contact Lens. 2014 Jul;40(4):225-31
pubmed: 24901974
Proc R Soc Med. 1965 Jan;58:9-20
pubmed: 14267505
Br J Ophthalmol. 2016 Jan;100(1):56-61
pubmed: 25966739
Vaccine. 2018 Nov 19;36(48):7408-7414
pubmed: 30420121
Ophthalmology. 2018 Nov;125(11):1682
pubmed: 30318037
MMWR Surveill Summ. 2017 May 05;66(11):1-28
pubmed: 28472027
Stat Med. 2016 Dec 30;35(30):5642-5655
pubmed: 27549016
Cornea. 2017 Mar;36(3):338-342
pubmed: 27741018
J Infect Dis. 2016 Jun 15;213(12):1872-5
pubmed: 26908728